QQQ   431.58 (+0.12%)
AAPL   168.66 (-2.33%)
MSFT   416.77 (+0.76%)
META   502.53 (+0.46%)
GOOGL   154.90 (+0.03%)
AMZN   184.30 (+0.37%)
TSLA   157.42 (-2.51%)
NVDA   872.34 (+1.43%)
AMD   163.88 (+2.22%)
NIO   3.83 (-1.54%)
BABA   69.41 (-1.71%)
T   16.06 (-1.11%)
F   12.12 (-0.90%)
MU   120.89 (-0.40%)
GE   155.12 (+0.92%)
CGC   6.90 (-1.15%)
DIS   114.17 (+1.08%)
AMC   2.74 (+10.93%)
PFE   25.87 (-0.15%)
PYPL   63.94 (+0.68%)
XOM   118.90 (-0.65%)
QQQ   431.58 (+0.12%)
AAPL   168.66 (-2.33%)
MSFT   416.77 (+0.76%)
META   502.53 (+0.46%)
GOOGL   154.90 (+0.03%)
AMZN   184.30 (+0.37%)
TSLA   157.42 (-2.51%)
NVDA   872.34 (+1.43%)
AMD   163.88 (+2.22%)
NIO   3.83 (-1.54%)
BABA   69.41 (-1.71%)
T   16.06 (-1.11%)
F   12.12 (-0.90%)
MU   120.89 (-0.40%)
GE   155.12 (+0.92%)
CGC   6.90 (-1.15%)
DIS   114.17 (+1.08%)
AMC   2.74 (+10.93%)
PFE   25.87 (-0.15%)
PYPL   63.94 (+0.68%)
XOM   118.90 (-0.65%)
QQQ   431.58 (+0.12%)
AAPL   168.66 (-2.33%)
MSFT   416.77 (+0.76%)
META   502.53 (+0.46%)
GOOGL   154.90 (+0.03%)
AMZN   184.30 (+0.37%)
TSLA   157.42 (-2.51%)
NVDA   872.34 (+1.43%)
AMD   163.88 (+2.22%)
NIO   3.83 (-1.54%)
BABA   69.41 (-1.71%)
T   16.06 (-1.11%)
F   12.12 (-0.90%)
MU   120.89 (-0.40%)
GE   155.12 (+0.92%)
CGC   6.90 (-1.15%)
DIS   114.17 (+1.08%)
AMC   2.74 (+10.93%)
PFE   25.87 (-0.15%)
PYPL   63.94 (+0.68%)
XOM   118.90 (-0.65%)
QQQ   431.58 (+0.12%)
AAPL   168.66 (-2.33%)
MSFT   416.77 (+0.76%)
META   502.53 (+0.46%)
GOOGL   154.90 (+0.03%)
AMZN   184.30 (+0.37%)
TSLA   157.42 (-2.51%)
NVDA   872.34 (+1.43%)
AMD   163.88 (+2.22%)
NIO   3.83 (-1.54%)
BABA   69.41 (-1.71%)
T   16.06 (-1.11%)
F   12.12 (-0.90%)
MU   120.89 (-0.40%)
GE   155.12 (+0.92%)
CGC   6.90 (-1.15%)
DIS   114.17 (+1.08%)
AMC   2.74 (+10.93%)
PFE   25.87 (-0.15%)
PYPL   63.94 (+0.68%)
XOM   118.90 (-0.65%)
NASDAQ:ANGO

AngioDynamics (ANGO) Stock Price, News & Analysis

$6.38
+0.07 (+1.11%)
(As of 11:50 AM ET)
Today's Range
$6.23
$6.38
50-Day Range
$5.27
$7.03
52-Week Range
$5.26
$11.38
Volume
97,010 shs
Average Volume
576,795 shs
Market Capitalization
$255.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.25

AngioDynamics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
125.1% Upside
$14.25 Price Target
Short Interest
Healthy
5.62% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.99
Upright™ Environmental Score
News Sentiment
1.46mentions of AngioDynamics in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
$67,000 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.57) to ($0.55) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.76 out of 5 stars

Medical Sector

48th out of 930 stocks

Surgical & Medical Instruments Industry

9th out of 99 stocks

ANGO stock logo

About AngioDynamics Stock (NASDAQ:ANGO)

AngioDynamics, Inc. provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease. The company's thrombus management portfolio includes AlphaVac system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac circuit is indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. In addition, it offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. The company also provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.

ANGO Stock Price History

ANGO Stock News Headlines

A.I. “Perfect Storm” Could Send THESE Stocks Sky High
A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.
A.I. “Perfect Storm” Could Send THESE Stocks Sky High
A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.
AngioDynamics: Fiscal Q3 Earnings Snapshot
AngioDynamics Q3 Loss Sharply Widens; Slashes FY24 Outlook
AngioDynamics Settles All Patent Litigation With C.R. Bard
See More Headlines
Receive ANGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AngioDynamics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
7/12/2023
Today
4/16/2024
Fiscal Year End
5/31/2024
Next Earnings (Estimated)
7/10/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:ANGO
CUSIP
03475V10
Employees
815
Year Founded
1988

Price Target and Rating

Average Stock Price Target
$14.25
High Stock Price Target
$18.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+125.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-52,440,000.00
Pretax Margin
-61.53%

Debt

Sales & Book Value

Annual Sales
$338.75 million
Cash Flow
$1.09 per share
Book Value
$9.64 per share

Miscellaneous

Free Float
38,012,000
Market Cap
$253.18 million
Optionable
Optionable
Beta
0.66

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives


ANGO Stock Analysis - Frequently Asked Questions

Should I buy or sell AngioDynamics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ANGO shares.
View ANGO analyst ratings
or view top-rated stocks.

What is AngioDynamics' stock price target for 2024?

4 Wall Street analysts have issued 1 year price targets for AngioDynamics' stock. Their ANGO share price targets range from $10.00 to $18.00. On average, they anticipate the company's share price to reach $14.25 in the next twelve months. This suggests a possible upside of 125.1% from the stock's current price.
View analysts price targets for ANGO
or view top-rated stocks among Wall Street analysts.

How have ANGO shares performed in 2024?

AngioDynamics' stock was trading at $7.84 at the start of the year. Since then, ANGO shares have decreased by 19.3% and is now trading at $6.33.
View the best growth stocks for 2024 here
.

Are investors shorting AngioDynamics?

AngioDynamics saw a decline in short interest in March. As of March 31st, there was short interest totaling 2,250,000 shares, a decline of 8.5% from the March 15th total of 2,460,000 shares. Based on an average daily trading volume, of 575,400 shares, the short-interest ratio is presently 3.9 days.
View AngioDynamics' Short Interest
.

When is AngioDynamics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 10th 2024.
View our ANGO earnings forecast
.

How were AngioDynamics' earnings last quarter?

AngioDynamics, Inc. (NASDAQ:ANGO) released its earnings results on Wednesday, July, 12th. The medical instruments supplier reported $0.02 EPS for the quarter, hitting analysts' consensus estimates of $0.02. The medical instruments supplier earned $91.10 million during the quarter, compared to analysts' expectations of $90.73 million. AngioDynamics had a negative trailing twelve-month return on equity of 3.48% and a negative net margin of 60.21%. The company's revenue was up 4.7% compared to the same quarter last year. During the same period last year, the business earned $0.01 earnings per share.

What ETF holds AngioDynamics' stock?

Invesco Nasdaq Future Gen 200 ETF holds 7,477 shares of ANGO stock, representing 0.65% of its portfolio.

What guidance has AngioDynamics issued on next quarter's earnings?

AngioDynamics updated its FY 2024 earnings guidance on Thursday, April, 4th. The company provided earnings per share guidance of -0.580--0.540 for the period, compared to the consensus EPS estimate of -0.430. The company issued revenue guidance of $270.0 million-$275.0 million, compared to the consensus revenue estimate of $312.1 million.

What is James C. Clemmer's approval rating as AngioDynamics' CEO?

34 employees have rated AngioDynamics Chief Executive Officer James C. Clemmer on Glassdoor.com. James C. Clemmer has an approval rating of 50% among the company's employees. This puts James C. Clemmer in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 47.0% of employees surveyed would recommend working at AngioDynamics to a friend.

What other stocks do shareholders of AngioDynamics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AngioDynamics investors own include General Electric (GE), Intel (INTC), Oasis Petroleum (OAS), Advanced Micro Devices (AMD), Freeport-McMoRan (FCX), Amicus Therapeutics (FOLD), Rigel Pharmaceuticals (RIGL), Accuray (ARAY), Celldex Therapeutics (CLDX) and Chimerix (CMRX).

How do I buy shares of AngioDynamics?

Shares of ANGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does AngioDynamics have any subsidiaries?
The following companies are subsidiares of AngioDynamics: AngioDynamics Canada Inc., AngioDynamics France SARL, AngioDynamics Medical Brasil Participacoes Ltda., AngioDynamics Netherlands B. V., AngioDynamics UK Limited, AngioDynamics VA LLC, Clinical Devices, Eximo Medical Ltd., FlowMedica, NM Holding Company Inc., Navilyst Medical Holdings Inc., Navilyst Medical Inc., Oncovionic, RITA Medical Systems, RITA Medical Systems LLC, RadiaDyne LLC, and Vortex Medical.
Read More
This page (NASDAQ:ANGO) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners